IL3RA and CD4+/CD56+ hematodermic neoplasm: Therefore, other CD123-targeting strategies are in development, including bispecific antibodies and combination therapies including tagraxofusp; adoptive T cell therapy using CAR-modified T cells targeting CD123 are under evaluation in BPDCN patients.